Feb 06, 2024 / 06:00AM GMT
Presentation
Feb 06, 2024 / 06:00AM GMT
=====================
Corporate Participants
=====================
* Keisuke Naito
Eisai Co., Ltd. - SVP, Chief Strategy, Planning & Ecosystem Officer and Acting Global Alzheimer's Disease Officer
* Lynn D. Kramer
Eisai Co., Ltd. - VP & Chief Clinical Officer - Alzheimer's Disease and Brain Health
* Mitsuru Shomon
Eisai Co., Ltd. - VP & CFO
* Takashi Owa
Eisai Co., Ltd. - Senior VP & Chief Scientific Officer - Japan and Asia Medical Safety
=====================
Conference Call Participants
=====================
* Fumiyoshi Sakai
UBS Investment Bank, Research Division - Research Analyst
* Hidemaru Yamaguchi
Citigroup Inc., Research Division - Research Analyst
* Kazuaki Hashiguchi
Daiwa Securities Co. Ltd., Research Division - Research Analyst
* Seiji Wakao
JPMorgan Chase & Co, Research Division - VP
* Shinichiro Muraoka
Morgan Stanley, Research Division - Research Analyst
======
Eisai Co Ltd
(HAM:EII)
€
21.13
+0.25 (+1.2%)
Market Cap: 6.13 Bil
Enterprise Value: 5.94 Bil
PE Ratio: 29.18
PB Ratio: 1.25
GF Score: 64/100 Q3 2024 Eisai Co Ltd Earnings Presentation Transcript
Feb 06, 2024 / 06:00AM GMT
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot